The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Roberta Brinton has looked at you know women with vascular risk so high cholesterol diabetes you know high blood sugar whatever that may be those patients are the one that respond preferentially to hormone replacement therapy
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
For symptomatic perimenopausal women under 60, hormone replacement therapy reduces all-cause mortality.
The breast-cancer risk attributed to HRT in the original WHI trial was overstated and the timing window matters most.